This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Neovasc's Tiara™ Transcatheter Mitral Valve Selected As A "best" New Device Concept At TCT 2012 Scientific Symposium

--Researchers Presented Positive Preclinical Data That Set the Stage for Longer-Term Tiara Studies Now Underway and Human Trials Planned for 2013--

--Researchers Also Presented Preliminary Registry Study Results Showing Improved Clinical  Status in Refractory Angina Patients Implanted with Neovasc Reducer™--

TSX Venture Exchange: NVC

VANCOUVER, Oct. 23, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that its Tiara™ transcatheter mitral valve in preclinical development for the treatment of mitral valve disease was selected for an oral presentation as a "Best" New Device Concept for 2012 during an opening session at the 24 th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.  Ten abstracts were selected for this honor from among 1750 abstracts submitted.  A second oral presentation of Tiara data is scheduled for tomorrow.  Researchers are also presenting Registry data showing that refractory angina patients implanted with the Neovasc Reducer™ have demonstrated improved clinical status and had no adverse events six months after implantation.

"This has been a very positive meeting for Neovasc as we continue to generate positive data that support the advancement of both the Tiara transcatheter mitral valve program and the Reducer, our device-based therapy for patients with refractory angina," noted Alexei Marko, CEO of Neovasc.  "Early Registry data for the Reducer confirm that patients exhibit significant, measurable clinical benefits post-implantation, and the Tiara program is generating a great deal of interest as the successful completion of our acute preclinical testing has enabled us to begin long-term animal safety studies.  If all goes well, we anticipate Tiara human trials will commence in 2013."

The Tiara program is a novel solution to treat mitral valve regurgitation, a serious and poorly served condition affecting millions of cardiac patients.  Current treatment options are limited since conventional surgical treatments are only appropriate for a small percentage of these patients. Tiara is intended to provide a minimally invasive transcatheter replacement for the mitral valve.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs